{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T18:49:57Z","timestamp":1791744597760,"version":"4.3.4"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007687","name":"Swedish Society of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007212","name":"Region Vastra Gotaland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007212","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy &amp; Behavior"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.yebeh.2024.109792","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T19:28:30Z","timestamp":1714073310000},"page":"109792","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Second antiseizure medication monotherapy in patients with adult-onset epilepsy: A register-based analysis"],"prefix":"10.1016","volume":"155","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2515-1434","authenticated-orcid":false,"given":"Konstantinos","family":"Polychronidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8681-0113","authenticated-orcid":false,"given":"Samuel","family":"H\u00e5kansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saman","family":"Hosseini Ashtiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9200-023X","authenticated-orcid":false,"given":"Andr\u00e9","family":"Ideg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8334-951X","authenticated-orcid":false,"given":"David","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9445-4545","authenticated-orcid":false,"given":"Johan","family":"Zelano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2024.109792_b0005","doi-asserted-by":"crossref","DOI":"10.1111\/epi.16610","article-title":"A pragmatic algorithm to select appropriate antiseizure medications in patients with epilepsy","author":"Asadi-Pooya","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.109792_b0010","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","article-title":"Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.yebeh.2024.109792_b0015","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.yebeh.2013.03.010","article-title":"When one plus one makes three: the quest for rational antiepileptic polytherapy with supraadditive anticonvulsant efficacy","volume":"27","author":"Brigo","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2024.109792_b0020","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/epi.17573","article-title":"Should substitution monotherapy or combination therapy be used after failure of the first antiseizure medication? Observations from a 30-year cohort study","volume":"64","author":"Hakeem","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.109792_b0025","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eplepsyres.2016.08.023","article-title":"Outcome of initial antiepileptic drug treatment in elderly patients with newly diagnosed epilepsy","volume":"127","author":"Bruun","year":"2016","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2024.109792_b0030","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/epi.17235","article-title":"Big data analysis of ASM retention rates and expert ASM algorithm: A comparative study","volume":"63","author":"Hakansson","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.109792_b0035","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/epi.16547","article-title":"The accuracy of using administrative healthcare data to identify epilepsy cases: A systematic review of validation studies","volume":"61","author":"Mbizvo","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.109792_b0040","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","article-title":"The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2024.109792_b0045","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/WNF.0b013e3180333069","article-title":"Monotherapy of lamotrigine versus carbamazepine in patients with poststroke seizure","volume":"30","author":"Gilad","year":"2007","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.yebeh.2024.109792_b0050","doi-asserted-by":"crossref","unstructured":"Consoli D, Bosco D, Postorino P, Galati F, Plastino M, Perticoni GF, et al. Study E. Levetiracetam versus carbamazepine in patients with late poststroke seizures: a multicenter prospective randomized open-label study (EpIC Project). Cerebrovasc Dis 2012;34: 282-9.","DOI":"10.1159\/000342669"},{"key":"10.1016\/j.yebeh.2024.109792_b0055","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1111\/epi.17226","article-title":"Antiseizure medication treatment pathways for US Medicare beneficiaries with newly treated epilepsy","volume":"63","author":"Terman","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2024.109792_b0060","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0140-6736(21)00247-6","article-title":"The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial","volume":"397","author":"Marson","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2024.109792_b0065","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1212\/WNL.0000000000004094","article-title":"The incidence of SUDEP: A nationwide population-based cohort study","volume":"89","author":"Sveinsson","year":"2017","journal-title":"Neurology"}],"container-title":["Epilepsy &amp; Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505024001732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505024001732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T00:14:23Z","timestamp":1726359263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505024001732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":13,"alternative-id":["S1525505024001732"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2024.109792","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second antiseizure medication monotherapy in patients with adult-onset epilepsy: A register-based analysis","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2024.109792","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109792"}}